Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
72.94
-0.77 (-1.04%)
At close: Nov 13, 2026, 4:00 PM EST
76.77
+3.83 (5.25%)
After-hours: Nov 13, 2026, 7:55 PM EST

Corcept Therapeutics Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Corcept Therapeutics stock has a consensus rating of "Buy" and an average price target of $142.6. The average 1-year stock price forecast is 95.50% higher than the current stock price, while the lowest is $50 (-31.45%) and the highest is $173 (+137.18%).

Price Target: $142.6 (+95.50%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$50$142.6$164$173
Change-31.45%+95.50%+124.84%+137.18%

Analyst Ratings

The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy423333
Buy111111
Hold100000
Sell000000
Strong Sell011111
Total645555

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$161
BuyReiterates$161+120.73%Nov 5, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$165
BuyMaintains$165+126.21%Nov 5, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$165 → $173
BuyReiterates$165 → $173+137.18%Nov 4, 2026
Truist Financial
Truist Financial
Buy
Initiates
$50 → $164
BuyInitiates$50 → $164+124.84%Aug 18, 2026
Wolfe Research
Wolfe Research
Sell
Maintains
$50
SellMaintains$50-31.45%Jul 30, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.16B
from 761.41M
Increased by 52.09%
Revenue Next Year
1.68B
from 1.16B
Increased by 44.73%
EPS This Year
2.13
from 0.82
Increased by 160.16%
EPS Next Year
4.22
from 2.13
Increased by 97.81%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
365.98M401.86M482.38M675.04M761.41M1.16B
Revenue Growth
3.42%9.80%20.04%39.94%12.79%52.09%
Gross Profit
360.70M396.47M475.89M664.16M748.43M1.14B
Gross Margin
98.56%98.66%98.66%98.39%98.30%98.40%
Operating Income
124.48M112.63M107.28M136.95M44.80M260.10M
Net Income
112.51M101.42M106.14M141.21M99.65M253.27M
EPS
----0.822.13
EPS Growth
-----33.33%160.16%
Forward PE
21.0119.9532.6132.1155.5334.19
Free Cash Flow
----141.79M298.00M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.2B
Avg1.2B
Low1.1B

Revenue Growth

Revenue Growth202620272028
High
57.4%
Avg
52.1%
Low
48.8%

EPS Forecast

EPS202620272028
High2.41
Avg2.13
Low1.84

EPS Growth

EPS Growth202620272028
High
193.9%
Avg
160.2%
Low
124.4%